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suggested by the comparison between real and simulated 
images. 
These results question the use of PET imaging as a target for 
dose painting by numbers in lung cancer. 
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Purpose or Objective: To determine the patterns of 
locoregional failure (LRF) in patients with locally advanced 
non-small cell lung cancer treated with definitive 
radiotherapy (RT). 
 
Material and Methods: One hundred and fifty-four patients 
from the Gating 2006 prospective randomized trial 
(NCT00349102) were treated with conformal RT with or 
without respiratory motion management. All patients had a 
PET-CT with 18FDG in the two months leading up to study 
inclusion. The recommended protocol prescription was 66 Gy 
in daily 2-Gy fractions, five days a week. IMRT was not 
permitted. Patients with a LRF as first event were included. 
Treatment plannings with simulation CT, pre-treatment 
18FDG PET-CT and post-treatment images demonstrating 
recurrence were registered and analyzed. Measurable LRF 
was contoured (rGTV) and classified as in-field (if 95% of 
rGTV volume was within the 95% isodose), marginal (if 20 to 
95% of rGTV volume was within the 95% isodose), or out-of-
field (if less than 20% of rGTV volume was within the 95% 
isodose). 
 
Results: Median follow-up was 27.8 months. Forty-eight 
patients presented LRF. One-year and 2-year locoregional 
disease-free survival were 77% (95% CI 70-83) and 72% (95% CI 
64-79) respectively. Age was the only independent LRF 
prognostic factor. The median age for patients in LRF was 67 
years vs 60 years for the group not in LRF (p=0.009). 79% of 
the patients with LRF as first event relapsed within the RT 
field. 32% of patients with LRF had a marginal LRF 
component. Isolated out-of-field failure occurred in only 3% 
of all patients. The regions of highest FDG-uptake on pre-
treatment PET-CT were located within the recurrence in 91% 
of patients with in-field LRF. 
 
Conclusion: In-field failure was the most common pattern of 
failure. Escalated dose RT with high-dose fractions guided by 
PET parameters warrants further investigation. 
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Purpose or Objective: Treatment of lung cancer (LC) with 
radiotherapy (RT) is often accompanied by the development 
of relapse. The significance of biologic markers for predicting 
recurrence has been increasingly emphasized by recent 
studies. Highly accurate and reliable machine-learning 
approaches can drive the success of biomarkers identification 
in clinical care. We developed a prospective platform to 
incorporate translational research into the clinical decision 
making process in LC patients. 
 
Material and Methods: Prospective data from 138 
consecutive LC patients with indication of 
radio(chemo)therapy and diagnosis from January 2013 to 
August 2014 were available to enable the development of a 
prediction model. Median age was 62.5 years-old (range, 35-
88) and the Karnofsky performance status (KPS) was ≥70 
except for 129 cases. The most common histology for non-
small cell LC patients (77.5%) was squamous cell carcinoma 
(52.3%). 73.1 percent of patients had Stage III disease (9 
cases were a mediastinum recurrence) and 91 % received 
platinum-based chemotherapy. Median total dose prescribed 
was 61.2 Gy. 20 cases also underwent surgery. Data from 
translational research included genotypes of 4 single 
nucleotide polymorphisms (SNPs) of the transforming growth 
factor (TGFB1) gene (rs4803455, rs1800468, rs8179181, and 
rs8110090) and 3 SNPs of the heat shock protein (HSPB1) gene 
(rs2868370, rs2868371, and rs7459185). 
 
Results: In univariate analysis, the CA genotype (N=92; 64 
relapses [70%]) of TGFB1 rs4803455 was associated with a 
statistically significantly higher risk of recurrence (OR = 2.09; 
P = 0.045) compared with the CC genotype (N=46; 24 relapses 
[52%]). This effect was virtually unchanged after multivariate 
analysis (OR = 2.31; 95% CI, 1.08– 4.95; P = 0.031). In 
addition, we performed an ROC curve analysis to determine 
the strength of the above identified biomarker in predicting 
relapse. Age was the most important predictor, with an AUC 
of 0.62. By adding the TGFB1 rs4803455 SNP, the predictive 
power of the recurrence risk model improved, enhancing the 
AUC to 0.67 (95% CI, 0.57– 0.76; P = 0.001). 
 
Conclusion: The prediction model for recurrence of patients 
with LC highlights the importance of combining patient, 
clinical, treatment, and translational variables. Our results 
showed that the CA genotype of TGFB1 rs4803455 SNP was 
associated with a higher risk of relapse in patients with LC 
treated with radio(chemo)therapy and thus may be used for 
guiding therapy intensity or as a selection criteria for a 
clinical trial, which would further the goal of individualized 
therapy. This tool could be used as a first building block for a 
decision support system. 
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Purpose or Objective: To evaluate loco-regional patterns of 
failure after induction chemotherapy and surgical resection 
for stage III N2 non–small-cell lung cancer (NSCLC). 
